Venus Remedies Limited, a research based global pharmaceutical company, has launched for the first time a research based product “Trois” in the Indian markets. This patent protected topical nano-emulsion is developed by using the integrated natural medicine approach to relieve from all kind of arthritic pain.

According to Dr Manu Chaudhary, joint managing director and director- Research, Venus Remedies Limited, the problem of arthritis is a constantly growing epidemic in India. As per the latest reports, almost 15 per cent of the Indian population is suffering from this crippling disease. We felt the pressing need to develop an alternative solution for rheumatic disorders and related infections, thus have come up for the first time with a topical nano emulsion “Trois” to relieve the Arthritic pain. At present, there are many biological products available in the markets for treating arthritis and related condition, but they have many side effects associated with them.

Prevailing treatment of rheumatoid diseases includes drugs such as non-steroidal, anti inflammatory drugs (NSAIDS), corticosteroids, slow acting anti-rheumatic drugs (SAARDS) or disease modifying drugs such as cyclophosphamide, methotrexate, gold salts, azothioprine, levamisole and the like. All these drugs have severe side effects and most of them are cytotoxic.

Trois is the most effective drug for the treatment of arthritis and is getting outstanding response in various markets across India.

“With the kind of response we are getting for this revolutionary nano tech emulsion in pain management as topical pain killer in arthritis, we are hopeful of capturing a significant share of the rheumatoid arthritis drug market in India, which is speculated to grow up to $672 million in 2013.” Trois has been awarded gold medal in 2011, under India Innovation Growth Program, organized by FICCI, Lockheed Martin and IC2 Institute, Texas, said Dheeraj Aggarwal, CFO, Venus Remedies Limited

“We have already filed patents for Trois in the major markets across the globe and based on the regulatory approvals, we are soon going to launch our products in the international markets as well,” added the Venus CFO.

Trois is indicated for the treatment of pain and inflammation as associated with osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, gouty arthritis, ankylosing spondylitis, psoriatic arthritis, backache, sprain and fibromyalgia.